VIDEO: Skyrizi promotes steroid-free clinical, endoscopic remission
Click Here to Manage Email Alerts
Maintenance therapy with Skyrizi boosted clinical and endoscopic outcomes in patients with Crohn’s disease, according to a presentation at the Congress of European Crohn’s and Colitis Organization.
Results from the FORTIFY study build on previously reported data from the ADVANCE and MOTIVATE trials on IV Skyrizi (risankizumab, AbbVie) induction in patients with moderate to severely active CD.
“Risankizumab maintenance was associated with high rates of steroid-free clinical and endoscopic remission, with a significantly higher proportion of patients being able to come off steroids and attain endoscopic response, endoscopic remission or deep remission,” Remo Panaccione, MD, FRCPC, professor of medicine and director of the Inflammatory Bowel Disease Group at the University of Calgary, told attendees. “I think this is really exciting for our field, as risankizumab has been shown to be highly effective in both induction and maintenance and now has been shown to meet our important clinical and endoscopic goals whilst sparing steroids.”
Collapse
Panaccione R, et al. Abstract DOP82. Presented at: Congress of European Crohn’s and Colitis Organization; Feb. 16-19, 2022 (virtual meeting).
Read more about
Click Here to Manage Email Alerts